We should have heard about Phase I oral NNZ2566 for concussion/Rett Syndrome. The Dec11 announcement said start would be Jan12.
Q2/3 2012 should then see the start of Phase II for oral NNZ2566.
We should also have heard about the Perseis in vivo assessment for cancer antibodies by Q4 2011.
Can't complain though. The oral NNZ2566 IND approval came early.
running shoes on., page-5
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$12.94 |
Change
-0.200(1.52%) |
Mkt cap ! $1.653B | |||
| Open | High | Low | Value | Volume |
| $13.03 | $13.06 | $12.75 | $7.500M | 581.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2300 | $12.93 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.96 | 2086 | 1 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| NEU (ASX) Chart |